Gamifant® (emapalumab-lzsg) – New orphan drug approval
November 20, 2018 - The FDA announced the approval of Sobi and Novimmune’s Gamifant (emapalumab-lzsg), for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
Top